Xueyuan Bai

机构：Nankai University, Wenzhou Medical University, State Administration of Traditional Chinese Medicine of the People's Republic of China, Chinese PLA General Hospital, Changchun University of Chinese Medicine, State Key Laboratory of Kidney Diseases · ORCID：0000-0001-9536-287X

发表论文 97 篇 · 总被引 8557 次 · h-index 32

代表论文

• Ginseng-derived nanoparticles alleviate inflammatory bowel disease via the TLR4/MAPK and p62/Nrf2/Keap1 pathways (2024 · Journal of Nanobiotechnology · 被引 82)
• Regulation of pericyte metabolic reprogramming restricts the AKI to CKD transition (2023 · Metabolism · 被引 56)
• The PI3K-Akt-mTOR pathway mediates renal pericyte-myofibroblast transition by enhancing glycolysis through HKII (2023 · Journal of Translational Medicine · 被引 42)
• Pyruvate kinase M2 regulates kidney fibrosis through pericyte glycolysis during the progression from acute kidney injury to chronic kidney disease (2023 · Cell Proliferation · 被引 36)
• ATGL regulates renal fibrosis by reprogramming lipid metabolism during the transition from AKI to CKD (2025 · Molecular Therapy · 被引 35)
• Complement factor B inhibitor LNP023 improves lupus nephritis in MRL/lpr mice (2022 · Biomedicine & Pharmacotherapy · 被引 31)